<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215720</url>
  </required_header>
  <id_info>
    <org_study_id>2010-012275-88</org_study_id>
    <secondary_id>2010/1626</secondary_id>
    <nct_id>NCT02215720</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>TORERO</acronym>
  <official_title>Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cetuximab is an EGFR inhibitor that has shown efficacy alone or in combination in colorectal
      cancer or head and neck cancer in several phase II/III studies.

      Temsirolimus is a new mTOR inhibitor that has shown interesting results in several Phase I/II
      studies in advance kidney cancer of bad prognosis.

      Study hypothesis is that combination of those two compounds and the inhibition of two
      pathways at the same time will have more efficiency on tumoral growth than the inhibition of
      those pathways in isolation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Assessed every every week from inclusion during the four first weeks then at week 8 then every 2 months until death or progression whichever comes first up to 24 months</time_frame>
    <description>Adverse effects will be assessed using NCI-CTC.AE v.4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Assessed every 2 cycles (44 days) from inclusion up to 24 months</time_frame>
    <description>Tumorous response will be assessed using RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Patients With Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab: 400mg/mÂ² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <arm_group_label>Cetuximab + Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with malignant tumor confirmed histologically or cytologically who does not
             respond to usual therapeutics or for whom there is no curative treatment

          -  Age &gt;/= 18 years

          -  ECOG 0 or 1

          -  Life expectancy &gt;/= 12 weeks

          -  Grade &lt;/=1 for all adverse effects related to previous therapy or surgery (except for
             alopecia)

          -  Appropriate organic functions as defined:

          -  ASAT and ALAT &lt;/= 2.5xLSN or ASAT and ALAT &lt;/= 5xLSN in case of inappropriate hepatic
             function due to the underlying disease

          -  Bilirubin &lt;/= 1.5xLSN

          -  Albumin &gt;/= 3.0 g/dL

          -  Neutrophil counts (PNN) &gt;/= 1 500/mL

          -  Platelets &gt;/= 100 000/mL

          -  Hemoglobin &gt;/= 9.0 g/dL

          -  Creatinin &lt;/= 1.5xLSN

          -  Cooperative patients able to respect the protocol

        Exclusion Criteria:

          -  Treatment by chemotherapy, radiotherapy, surgery or the two compounds of the study
             within 4 weeks before the inclusion

          -  Previous treatment with an association of mTOR inhibitor or EGFR inhibitor

          -  Diagnosis of a secondary cancer within the last 3 years except for a basal-cell
             carcinoma, cutaneous spinocellular cancer or in situ carcinoma well treated

          -  Grade &gt;/= 2 nephropathy according to NCI CTCAE

          -  Current treatment with curative dose of coumadin or heparin of low molecular weight

          -  Previous uncontrolled brain metastases, medullar compression or carcinomatosis
             meningitis or any proof of leptomeningeal pathology or metastasis.

          -  Presence of one og those pathologies during the last 12 months before the inclusion:

          -  myocardial infarction

          -  angina pectoris

          -  bypass of coronal or peripheral arteries

          -  heart failure

          -  stroke

          -  cerebral bleeding

          -  pulmonary embolism

          -  Grade 3 bleeding according to NCI CTCAE criteria less than 3 weeks before treatment
             start

          -  Uncontrolled high blood pressure (&gt;150/100mhHg)

          -  Grade &gt;/=2 heart rate disorder, atrial fibrillation whichever the grade, lengthen of
             QTC &gt;450 msec for male or &gt;470 msec for female.

          -  Patients HIV positive

          -  Pregnant or breastfeeding woman

          -  Patients with psychiatric disorder

          -  Active alcoholism

          -  Previous pulmonary interstitial disease

          -  Previous hypersensitivity to antihistamine treatment and/or medical contraindication
             for an antihistamine or corticoid treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SORIA Jean Charles, MD, PhD</last_name>
    <phone>0142114291</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-charles.soria@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HASSELBERG Rudiger, MD,PhD</last_name>
    <phone>0142116250</phone>
    <phone_ext>+33</phone_ext>
    <email>rudgier.hasselberg@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudiger HASSELBERG</last_name>
      <phone>0142116250</phone>
      <phone_ext>+33</phone_ext>
      <email>rudiger.hasselberg@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Charles SORIA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

